Literature DB >> 2157775

Erythropoietin receptor: cloning strategy and structural features.

A D'Andrea1, G Fasman, G Wong, H Lodish.   

Abstract

We recently isolated a cDNA clone encoding the murine erythropoietin (Epo) receptor from a PXM expression library made from uninduced murine erythroleukemia cells. The clone was identified by screening COS cell transfectants for internalization of radiolabeled recombinant human Epo. As inferred from the cDNA sequence, the murine Epo receptor (Epo-R) is a 507 amino acid polypeptide with a single membrane-spanning domain. Extensive homology was found between the Epo-R and the interleukin 2 receptor beta chain, both at the level of amino acid sequence and at the level of regional hydrophobicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157775     DOI: 10.1002/stem.5530080716

Source DB:  PubMed          Journal:  Int J Cell Cloning        ISSN: 0737-1454


  7 in total

1.  Biological inducers of haemopoietic differentiation.

Authors:  S Eridani; E Abood
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

Review 2.  Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Authors:  Sara Gardenghi; Robert W Grady; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2010-10-15       Impact factor: 3.722

3.  Future alternative therapies for β-thalassemia.

Authors:  Stefano Rivella; Eliezer Rachmilewitz
Journal:  Expert Rev Hematol       Date:  2009-12-01       Impact factor: 2.929

4.  Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.

Authors:  Ilaria V Libani; Ella C Guy; Luca Melchiori; Raffaella Schiro; Pedro Ramos; Laura Breda; Thomas Scholzen; Amy Chadburn; YiFang Liu; Margrit Kernbach; Bettina Baron-Lühr; Matteo Porotto; Maria de Sousa; Eliezer A Rachmilewitz; John D Hood; M Domenica Cappellini; Patricia J Giardina; Robert W Grady; Johannes Gerdes; Stefano Rivella
Journal:  Blood       Date:  2008-05-14       Impact factor: 22.113

Review 5.  The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.

Authors:  Kenneth Kaushansky
Journal:  Best Pract Res Clin Haematol       Date:  2007-03       Impact factor: 3.020

Review 6.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Authors:  Laura Breda; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

7.  beta-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload.

Authors:  Luca Melchiori; Sara Gardenghi; Stefano Rivella
Journal:  Adv Hematol       Date:  2010-05-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.